Abstract: A core-shell gel particle of the invention contains a crosslinked hyaluronic acid, has a higher equilibrium swelling capacity at the surface than at the center, the equilibrium swelling capacity showing a change curve with an inflection point from the center to the surface, and has a probe pushing force of 20 nN or less from the surface to a depth of 800 nm.

Abstract: Provided is an agent for preserving a biological component, comprising a hydrogel, the hydrogel comprising a crosslinked product formed from a compound having a plurality of hydroxyl groups and a modified hyaluronic acid having substituents capable of reacting with the hydroxyl groups to form a crosslinked structure.

Abstract: A core-shell gel particle of the invention contains a crosslinked hyaluronic acid, has a higher equilibrium swelling capacity at the surface than at the center, the equilibrium swelling capacity showing a change curve with an inflection point from the center to the surface, and has a probe pushing force of 20 nN or less from the surface to a depth of 800 nm.

Abstract: Provided is an agent for preserving a biological component, comprising a hydrogel, the hydrogel comprising a crosslinked product formed from a compound having a plurality of hydroxyl groups and a modified hyaluronic acid having substituents capable of reacting with the hydroxyl groups to form a crosslinked structure.

Abstract: A core-shell gel particle of the invention contains a crosslinked hyaluronic acid, has a higher equilibrium swelling capacity at the surface than at the center, the equilibrium swelling capacity showing a change curve with an inflection point from the center to the surface, and has a probe pushing force of 20 nN or less from the surface to a depth of 800 nm.

Abstract: The present invention provides a crosslinked hyaluronic acid composition including self-crosslinking hyaluronic acid particles having an equilibrium swelling capacity of 3-fold to 10-fold, and an aqueous solvent, wherein a dry weight of the self-crosslinking hyaluronic acid particles based on the total volume of the crosslinked hyaluronic acid composition is 3 w/v % to 8 w/v %. The crosslinked hyaluronic acid composition of the invention uses self-crosslinking hyaluronic acid particles of which the equilibrium swelling capacity is within the above predetermined range. Accordingly, the viscosity does not sharply increase even if the concentration thereof is increased. Therefore, if the crosslinked hyaluronic acid composition is applied to an injection, it is possible to obtain a sufficient curative effect on knee osteoarthritis even with a small frequency of administration.

Abstract: Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).

Abstract: The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof.

Abstract: The present invention provides a crosslinked hyaluronic acid composition including self-crosslinking hyaluronic acid particles having an equilibrium swelling capacity of 3-fold to 10-fold, and an aqueous solvent, wherein a dry weight of the self-crosslinking hyaluronic acid particles based on the total volume of the crosslinked hyaluronic acid composition is 3 w/v % to 8 w/v %. The crosslinked hyaluronic acid composition of the invention uses self-crosslinking hyaluronic acid particles of which the equilibrium swelling capacity is within the above predetermined range. Accordingly, the viscosity does not sharply increase even if the concentration thereof is increased. Therefore, if the crosslinked hyaluronic acid composition is applied to an injection, it is possible to obtain a sufficient curative effect on knee osteoarthritis even with a small frequency of administration.

Abstract: Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).

Abstract: Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).

Abstract: The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof.

Abstract: In a pair of adjacent stack contact and stack contact in the semiconductor device, the plugs and the plugs are disposed so that a center-to-center distance of the plugs extending through a second interlayer insulating film, which is thicker than the first interlayer insulating film, is larger than a center-to-center distance of the plugs extending through the first interlayer insulating film.